1. Home
  2. LQDA vs WRBY Comparison

LQDA vs WRBY Comparison

Compare LQDA & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$37.97

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Warby Parker Inc.

WRBY

Warby Parker Inc.

HOLD

Current Price

$21.33

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
WRBY
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LQDA
WRBY
Price
$37.97
$21.33
Analyst Decision
Strong Buy
Buy
Analyst Count
11
11
Target Price
$41.00
$27.10
AVG Volume (30 Days)
1.0M
2.0M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
51.81
105.88
EPS
N/A
0.01
Revenue
$158,320,000.00
$871,905,000.00
Revenue This Year
$278.87
$14.48
Revenue Next Year
$57.13
$16.41
P/E Ratio
N/A
$2,260.00
Revenue Growth
1031.18
13.04
52 Week Low
$11.85
$14.96
52 Week High
$46.67
$31.00

Technical Indicators

Market Signals
Indicator
LQDA
WRBY
Relative Strength Index (RSI) 51.95 43.22
Support Level $35.00 $20.97
Resistance Level $39.19 $22.64
Average True Range (ATR) 1.94 1.44
MACD -0.21 -0.07
Stochastic Oscillator 36.31 17.86

Price Performance

Historical Comparison
LQDA
WRBY

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Share on Social Networks: